FENC today
$10.64+$0.06 (+0.57%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourExpanding
1 hourExpanding
15 minSymmetric Triangle
5 minStrong Bullish
Daily trend turns up above $13.25
Key levels
Resistance$12.69
Resistance$11.25
Support$9.93
Support$9.20
Latest news & SEC filings
EarningsFennec Pharmaceuticals posts $0.12 per-share profit, revenue of $19.608M for third quarter
EarningsFennec Pharmaceuticals sets date for Q3 2026 earnings release
SEC FilingFennec Pharmaceuticals Inc. filed an insider trading report (Form 4)
All FENC news →About Fennec Pharmaceuticals
Fennec Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapies for cancer patients. Its main product is PEDMARK, a sodium thiosulfate solution approved to reduce the risk of hearing loss in pediatric patients receiving certain chemotherapy. The company operates primarily in the United States and licenses related intellectual property from academic institutions.
Based on the company's 10-K filed Mar 27, 2026.
Nasdaq · Healthcare
FENNEC PHARMACEUTICALS INC. (FENC)
What Is the Price Target for FENC?
SEPT Low Target
$16.00
SEPT Mid Target
$16.00
SEPT High Target
$16.00
Analyst Consensus
$16.00
Is FENC a Buy or Sell Right Now?
Thesis
- •Revenue growing -6.1% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for FENC.
Start Free Trial →Is FENC Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$12.00
20
Moat Score
NONE
1/9
Piotroski Score
1.9
Altman Z-Score
What Is Smart Money Doing with FENC?
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Cioffi Christiana Marie | officer | Buy | 156 | - | Sep 30, 2026 |
| Sayad Pierre Sargis | officer | Buy | 168 | - | Sep 30, 2026 |
| Evans Terry L | officer | Buy | 168 | - | Sep 30, 2026 |
| Hackman Jeffrey S. | director officer | Buy | 1,159 | - | Sep 30, 2026 |
| Andrade Robert | officer | Buy | 1,703 | - | Sep 30, 2026 |
| Raykov Rosty | other | Sale | 10,000 | $121K | Sep 1, 2026 |
| Cioffi Christiana Marie | officer | Buy | 156 | - | Aug 31, 2026 |
| Sayad Pierre Sargis | officer | Buy | 168 | - | Aug 31, 2026 |
| Sayad Pierre Sargis | officer | Sale | 12,000 | $146K | Aug 31, 2026 |
| Evans Terry L | officer | Buy | 168 | - | Aug 31, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →FENC Growth Story
Revenue YoY
-6.1%
3yr Revenue CAGR
207.5%
EPS Growth YoY
-1600%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for FENC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for FENC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:06 | $10.64 | 1,263 | $$13K | SELL |
| 20:41:15 | $10.76 | 5,000 | $$54K | SELL |
| 20:36:42 | $10.75 | 6,888 | $$74K | SELL |
| 20:25:54 | $10.78 | 5,900 | $$64K | BUY |
| 20:25:54 | $10.80 | 1,100 | $$12K | BUY |
5 dark pool trades shown · $$217K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for FENNEC PHARMACEUTICALS INC. (FENC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →FENC — frequently asked questions
What is FENC stock price today?
FENNEC PHARMACEUTICALS INC. (FENC) is at $10.64, up 0.57% (+$0.06) at the Nov 11, 2026 close.
Why is FENC stock moving today?
Latest FENC news — Nov 12, 2026: Fennec Pharmaceuticals posts $0.12 per-share profit, revenue of $19.608M for third quarter · Nov 4, 2026: Fennec Pharmaceuticals sets date for Q3 2026 earnings release
What is the FENC price target?
The average analyst price target for FENC is $16.00, ranging from $16 to $16, based on 3 analysts.
What do analysts rate FENC?
Analyst ratings for FENC: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did FENC beat earnings?
FENC last reported on Aug 11, 2026: EPS $0.05 vs $0.02 expected — a beat of 150.0%.
Does FENC pay a dividend?
FENC does not currently pay a dividend.
What are FENC support and resistance levels?
Support: $9.93, $9.20, $8.52. Resistance: $11.25, $12.69.
What are insiders doing with FENC?
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
What is the latest news on FENC?
Nov 12, 2026: Fennec Pharmaceuticals posts $0.12 per-share profit, revenue of $19.608M for third quarter · Nov 4, 2026: Fennec Pharmaceuticals sets date for Q3 2026 earnings release · Nov 2, 2026: Fennec Pharmaceuticals Inc. filed an insider trading report (Form 4)